Navigation Links
Pathway That Degrades Holiday Turkey Fuels Metastasis of Triple Negative Breast Cancer

(PRWEB) December 10, 2014

A University of Colorado Cancer Center study being presented at the San Antonio Breast Cancer Symposium shows that triple negative breast cancer cells process tryptophan to promote survival while traveling through the body in order to seed new tumor sites.

"I'm not saying that people with metastatic breast cancer shouldn't eat turkey during the holidays, but triple-negative breast cancer appears to have found a way to process tryptophan more quickly, equipping cancer cells to survive while in circulation, which allows them to metastasize," says Thomas Rogers, the paper's first author and PhD candidate in the laboratory of CU Cancer Center investigator, Jennifer Richer, PhD.

When healthy cells become detached from the foundation on which they grow, they are programmed to undergo cell death through a process known as anoikis ("without a home" in Greek). This means that in order to metastasize, cancer cells have to evade anoikis - they have to survive while in suspension, unattached from a foundation. The current study used a gene array to discover which genes were upregulated in triple negative breast cancer cells that were able to grow in suspension compared with cells that were still attached to a substrate.

"Basically, we asked what is different in cells that are able to survive being detached," Rogers says.

Many of the gene expression changes in the triple negative breast cancer cells that had learned to survive detachment were in a single metabolic pathway - the kynurenine pathway, which is responsible for degrading the essential amino acid tryptophan. The faster the kynurenine pathway, the faster tryptophan is degraded. Controlling the speed of the kynurenine pathway is the enzyme TDO2 - which happened to be the most upregulated gene in detached compared to attached triple-negative breast cancer cells.

In other words, it may be that cancer cells over-express TDO2, which speeds up the whole kynurenine pathway, and degrades more tryptophan - all of which helps these cells to escape anoikis, which allows them to survive long enough to pick up roots and move to other places in the body.

"When a cancer cell detaches and cranks up this catabolic pathway, it can metabolize tryptophan faster and promote survival," Rogers says.

Currently, drugs targeting other enzymes in the complex chain of the kynurenine pathway are already in clinical trials. For example the drug indoximod by New Link Genetics is being tested in combination with chemotherapy against metastatic breast cancer ( number NCT01792050). This drug adjusts features within the pathway to help the body's immune system more effectively target cancer cells.

"We hope that looking at other targets in this pathway could create a more effective therapy," Rogers says. "Indoximod or other compounds like it could be used in combination to not only boost the immune system to target free-floating cancer cells, but also to re-sensitize cancer cells to the programmed cell death of anoikis."

Read the full story at

Source: PRWeb
Copyright©2014 Vocus, Inc.
All rights reserved

Related biology technology :

1. Decades-old conclusion about energy-making pathway of cyanobacteria is corrected
2. bioTheranostics Launches Precision Medicine Biomarkers for Tumor Pathway Interrogation
3. More evidence for longevity pathway
4. Alliance for Safe Biologic Medicines Chairman Urges FDA to Ensure that Patient Safety is the Cornerstone of Biosimilar Pathway
5. Immune Deficiency Foundation Urges FDA To Exempt Immunoglobulin From Biosimilars Pathway
6. Merrimack Pharmaceuticals To Present Preliminary Clinical Data For Novel Therapies Targeting Molecular Pathways In Advanced Cancers
7. Leuven research opens new pathway for the treatment of Alzheimers disease
8. Pathway BioLogic is Chosen by Easy Gardener to Formulate the U.S.’s First Microbial Enhanced Natural Water Soluble Plant Food
9. New study validates longevity pathway
10. Elsevier Launches Web-Based Pathway Studio and Adds New Molecular Data from Its Biology Journals to Boost Early Discovery Research
11. NewLink Genetics Initiates Phase 2 Trial of IDO Pathway Inhibitor, Indoximod, for the Treatment of Metastatic Breast Cancer
Post Your Comments:
(Date:6/6/2019)... (PRWEB) , ... June 05, 2019 , ... WCCT ... and medical device industries, announced today that they will be receiving 3 awards at ... Diego, CA. WCCT received 2 awards in the categories of overall Quality and Compatibility ...
(Date:5/31/2019)... ... May 30, 2019 , ... ... to demonstrate an efficient delivery system for the sustained release of human placental ... plasma-based gel system was able to deliver CM into the injured kidney, where ...
(Date:5/14/2019)... TOWNSHIP, N.J. (PRWEB) , ... May 13, 2019 ... ... of custom built, helium-based leak testing instruments for the Pharmaceutical, Biotechnology, Medical Device ... new company website. The redesigned website aims to improve LDA’s ability to ...
(Date:5/4/2019)... ... May 03, 2019 , ... Diopsys ... Diopsys® ffERG/Photopic Negative Response vision test, a new full field electroretinography ... is estimated that 6.3 million Americans will have glaucoma, with black Americans having ...
Breaking Biology Technology:
(Date:5/24/2019)... , ... May 24, 2019 , ... The newest edition ... is now available on the company’s global website. , Crystallography Times is a monthly ... X-ray diffraction. It serves the X-ray analysis community by presenting the latest news and ...
(Date:5/23/2019)... , ... May 23, 2019 , ... ... Agents for sales and service organizations, today announced its inclusion in DMG ... Solutions as the intelligent virtual agent (IVA) market share leader, based on number ...
(Date:5/21/2019)... ... May 21, 2019 , ... Experiential tourism, a trend encompassing culinary travel, ... last several years. And according to a recent report by Skift, a media ... fact, more and more travelers are wanting their journeys to be authentic and unique, ...
Breaking Biology News(10 mins):